Amgen strikes Enbrel 'outcomes' contract with Harvard Pilgrim

Pfizer's new Inflectra biosim data puts J&J's Remicade on notice in Crohn's

Roche lawsuit blasts Amgen for 'about-face' on biosimilar patent fights

Amgen's Repatha wins in outcomes trial, but is the score high enough?

Amgen sets 'reasonable expectations' with lower 2017 sales guidance: analyst

After a contentious review, cost watchdog ICER rolls out updates to framework

Amgen claims Sanofi, Regeneron 'resort to hyperbole,' 'scare tactics' in PCSK9 appeal